Pfizer has completed its $5.4-billion acquisition of Global Blood Therapeutics (GBT), a San Francisco, California-based bio/pharmaceutical company focused on sickle cell-disease. The companies had announced the acquisition in August (August 2022).

GBT’s lone commercial product is Oxbryta (voxelotor) for treating sickle-cell disease.  It was approved in the US in November 2019 and is also approved in the European Union, United Arab Emirates, Oman, and Great Britain. It had 2021 net sales of $195 million. Pfizer estimates that GBT’s pipeline and Oxbryta have the potential for a sickle-cell disease franchise that could achieve combined worldwide peak sales of more than $3 billion.

Key pipeline assets of GBT are inclacumab, in Phase III development, to address pain crises associated with sickle-cell disease, and GBT021601, a sickle hemoglobin polymerization inhibitor, in Phase II of Phase II/III trials. Both products have received orphan drug and rare pediatric disease designations from the US Food and Drug Administration.

Pfizer acquired all of the outstanding shares of common stock of GBT for $68.50 per share in cash for an estimated total enterprise value of approximately $5.4 billion, including debt and net of cash acquired.

Source: Pfizer